

Leadership Chair: Philip A. Philip, MD, PhD, FRCP Vice-Chair: Elena Gabriela Chiorean, MD, FASCO Executive Officer: Christopher W. Ryan, MD Statisticians: Katherine A. Guthrie, PhD Sarah Colby, MS Sara Threlkel, BS Scientific Leadership		
Gastroesophageal:Syma Iqbal, MD	Clinical Trials Program Manager:	
Zev A. Wainberg, MD	Cililical Illais i Tograffi Manager	Laura Gilurici, MS
Pancreatic: Davendra P.S. Sohal, MD	- . ,,	
	Time/Location	400
Hepatobiliary: Anthony B. El-Khoueiry, MD	Friday, September 19, 2025 4:30 p.m.	•
	Room: Regency D (Ballroom Level, W	rest lower)
Syed A. Ahmad, MD (Surgical representative)	Age	enda
Colon:	1. Welcome	
	2. Announcements & Introductions	Philip Philip
Neuroendocrine Tumors:Nageshwara Arvind Dasari, MD		E. Gabriela Chiorean
Aman Chauhan, MD	3. HEARD Subcommittee Initiatives	Rachel Safyan, Colmar Figueroa
Ano-Rectal: Lisa A. Kachnic, MD		Moseley, Carole Seigel,
Hagen F. Kennecke, MD		Marielle McLeod
Imaging:		
Pathology:	4. Updates in Targeted Therapies for	
Radiation Oncology: Lisa A. Kachnic, MD		Marwan Fakih
Surgery: Stephen W. Behrman, MD	5. SWOG Led Active Trials	
	a. S1922	Michael Overman
	b. S2001	Vincent Chung
Translational Medicine:	c. S2104	Heloisa Soares/S. Ahmad
	d. S2107	Van Morris
HEARD:	e. S2012	David Zhen/E. Gabriela Chiorean
	f. S2303	Anwaar Saeed/Paul Oberstein
Designates Cancer Control Liaisons:	g. S2408	Jonathan Sham/Venu Pillarisetty
	h. S2433	Rachael Safyan/E. Gabriela Chiorean
Community Liaisons: Gary L. Buchschacher, MD, PhD (Medical Onc)	6. Gastroesophageal	Syma Iqbal, Zev Wainberg
	a. Major recent clinical results	
Flavio Rocha, MD (Surgical)	b. NCTN trials update	
	c. Future SWOG plans	
AYA Committee Liason:	·	5
Veterans Affairs:	7. Pancreatic	Davendra Sohal, Andrew Lowy
Data Coordinators:	a. Major recent clinical results	
Alex Rangel	b. NCTN trials update	
Brian Zeller	c. Future SWOG plans	

8. Colon

Marwan Fakih, Philip Gold, Sepideh Gholami

Hagen Kennecke, Lisa Kachnic

Arvind Dasari, Aman Chauhan

Anthony El-Khoueiry

Rachna Shroff

- a. Major recent clinical results
- b. NCTN trials update
- c. Future SWOG plans
- 9. Anal and Rectal
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans
- 10. Hepatobiliary
- a. Major recent clinical results
- b. NCTN trials update
- c. Future SWOG plans
- 11. Neuroendocrine
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans
- 12. Discussion/Other business
- 13. Adjourn

Gastroesophageal

Active Studies

- S2303, "Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)." Study Chairs: Dr. Saeed, and Dr. Oberstein. Activated: 5/6/24
- A022102, "Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma." SWOG Champion: Dr. Oberstein. Activated: 1/17/19.
- **EA2174**, "A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma." SWOG Champion: Dr. Kelly. Activated: 1/17/19. Temporarily Closed to Accrual as of 12/29/22.
- **EA2212**, "A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer." SWOG Champion: Emerson Chen Temporarily Closed to Accrual as of 12/4/24

EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)." SWOG Champion: Dr. Horowitz. Activated: 2/6/20.

Closed Studies

<u>A021302</u>, "Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study." SWOG Champion: S. Iqbal. Activated by SWOG: 4/1/16.

Pancreatic

Developing Studies

52433, "Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma." Study Chairs: R. Safyan, E. Chiorean, H. Singh

Active Studies

- **S2408**, "A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula." Study Chairs: J. Sham, V. Pillarisetty, R. Krouse. Activated: 2/14/25
- **S2001**, "Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations." Study Chair: Dr. Chung. Activated: 12/4/20.
- A022106, "A Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/ Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)." SWOG Champion: G. Botta
- A021804, "A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma." SWOG Champion: Dr. C. Lopez. Activated: 11/2/20.
- <u>A021806</u>, "A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer." SWOG Champion: Dr. Noel. Activated: 7/1/20.
- **EA2192**, "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation." SWOG Champions: Drs. Chiorean and Philip. Activated: 4/29/21.

Closed Studies Hepatobiliary

- **EA2186**, "A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)." Activated: 6/18/20. SWOG Champion: Dr. Zhen. Closed to Accrual as of 10/17/23
- RTOG-0848, "Gemcitabine, with and without Erlotinib, Followed by a Second Randomization with and without Chemoradiation, as Adjuvant Treatment for Pancreatic Head Cancer: A Phase III RTOG/SWOG/NCIC/EORTC Study." SWOG Champion: P. Philip. Closed to accrual as of 1/18/19
- A021501, "Preoperative Extended Chemotherapy vs Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas." SWOG Champion: S. Ahmad. Closed to accrual as of 5/6/19
- **EA2161**, "A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)." 12/27/19: Closed to Accrual & Treatment

Neuroendocrine

Active Studies

- **S2104**, "Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors." Study Chairs: Dr. Soares, S. Ahmad.. Activated: 10/14/21
- **S2012**, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)." Study Chairs: Drs. D. Zhen, E. Chiorean, E. Burgess, E. Swisher, L. Byers. Activated: 12/2/21

Closed Studies

- A021602, "Randomized Double-Blinded Phase III Study of CABozantinib versus Placebo IN Advanced NEuroendocrine Tumors after Progression on Prior Therapy (CABINET)." SWOG Champion: Dr. Strosberg. Activated: 7/18/18. Closed to Accrual as of 9/8/23
- **EA2142**, "Randomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas." SWOG Champion: H. Soares, Closed to Accrual & Treatment: 4/1/21

Active Studies

- NRG-GI003, "A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma." SWOG Champion: Dr. El-Khoueiry. Activated: 6/21/17.
- EA2197, "Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial." SWOG Champion: Dr. Rocha. Activated: 12/22/20.

Closed Studies

- S1815, "A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers." Study Chair: Dr. Shroff. Activated: 12/3/18. Permanently Closed: 2/15/21.
- **EA2187**, "A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma." SWOG Champion: Dr. Stein. Activated: 1/31/20. Permanently Closed: 3/22/23.
- RTOG-1112, "Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma." L. Dawson. SWOG Champion: T. Mitin

Colorectal

Active Studies

- S1922, "Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma." Study Chair: M. Overman, Activated: 12/16/19
- A021502, "Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC)." SWOG Champion: G. Lieu Closed to Accrual as of 1/17/23
- A022101, "A Pragmatic Randomized Phase III Trial Evaluating Total
 Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer:
 Evaluating Radiation, Ablation, and Surgery (ERASur)." SWOG Champion:
 S. Gholami Activated: 1/10/23.
- EA2222, "A Randomized Phase III Study of Systemic Therapy with or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial" Activated: 10/19/23. SWOG Champion: Skye C. Mayo, MD, MPH

- NRG-GI008, "Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)." SWOG Champions: P. Philip & C. Eng Activated: 3/10/22
- NRG-GI004/ S1610, "Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer." SWOG Champion: Dr. Overman. Activated: 11/7/17.

Closed Studies

- **S2107**, "Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab for Patients with Microsatellite Stable, BRAFV600E Metastatic Colorectal Cancer." Study Chair: Dr. Morris. Study closed to accrual 10/1/24
- S1613, "A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification." Study Chair: Dr. Raghav. Activated: 10/19/17. Step 3 permanently closed: 11/30/23
- So820, "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Study Chair: Dr. Zell. Activated: 3/1/13. Permantley Closed: 6/30/23
- A021502, "Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair." SWOG Champion: Dr. Lieu. Activated: 9/12/17. Permantley Closed: 1/17/23
- A021703, "Randomized Double-Blind Phase III Trial of Vitamin D3
 Supplementation in Patients with Previously Untreated Metastatic
 Colorectal Cancer (SOLARIS)." SWOG Champion: Dr. Cohen. Activated: 9/30/19. Permantley Closed: 12/15/22
- E7208, "A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy." SWOG Champion: H. Hochster. Accrual target: 147 / Final accrual: 136

NRG-GI005, "Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)." SC: A. Scott. SWOG Champion: A. Scott Closed to Accrual as of 2/12/24

Anal

Active Studies

- A022104, "The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer." SWOG Champion: A. Dasari, Activated 11/9/22.
- **EA2176**, "Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients." SWOG Champion: Dr. Morris. Activated: 10/15/20.
- **EA2182**, "A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)." SWOG Champion: Dr. Murphy. Activated: 11/12/19.
- **EA2201**, "A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma." SWOG Champion: Dr. Cho. Activated 5/13/21.

Closed Studies

- N1048, "A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision." SWOG Champion: C. Eng. Activated: 4/15/12. Accrual target: 1120 / Final accrual: 1194
- InterAACT EA2133, "An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-Fluorouracil Versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease." SWOG Champion: V. Morris. Activated: 2/15/16. Accrual target: 80 / Final accrual: 12
- NRG-G1002, "A Phase II Clinical Trial Platform of Sensitization Utilizing
 Total Neoadjuvant Therapy (TNT) in Rectal Cancer." Activated: 10/12/16.
 Accrual target: 348/ SWOG accrual: 12 / Final accrual: 363. SWOG
 Champion: L. Kachnic
- EA2165, "A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer." NCTN activated: 4/13/18. Accrual target: 344 / SWOG accrual: 38 / Final accrual: 383 SWOG Champion: V. Morris

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Spring 2025 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

52303 S2303: Phase II/III Trial of Nivolumab + Paclitaxel + Ramucirumab in Gastric and Esophageal Adenocarcinoma (PARAMUNE). Saeed A, Colby S, Oberstein P, Duda D, Park R, Agarwal R, Figueroa Moseley C, Vaidya R, Unger J, Guthrie K, Rocha F, Senthil M, Safyan R, Wainberg Z, Iqbal S, Chiorean EG, Philip P. Future Oncology May;21(11):1325?1331, 2025. https://pubmed.ncbi.nlm.nih.gov/40155326/

Submitted Manuscripts

None this cycle

	<i>\$1922</i>	S2001	<i>S2104</i>	S2107	<i>\$2303</i>	A021806	A022001	A022101	A022102
Banner University Medical Center - Tucson	-	-	9	-	-	1	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	2	-	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Boston Medical Center	-	-	-	-	-	1	-	-	3
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	2	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	2	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	1	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	1	2	2	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	1	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	6	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	1	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	2	3	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	2	-	-	2	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	3	-	-	-	1	-
Heartland Cancer Research NCORP	1	1	-	3	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	2	-	-	-	-	-	-	-
Henry Ford Hospital	-	2	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	1	-	-	6	3	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	1	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	2	2	-	4	3	-	-	-	-
Moffitt Cancer Center	-	-	2	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	1	-	1	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	1	-	-	-
Northwestern University LAPS	1	-	1	-	-	1	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	1	-	-	-	-	-	-
Oregon Health and Science University	-	-	1	-	3	3	-	-	-

	<i>\$1922</i>	S2001	S2104	S2107	<i>S2303</i>	A021806	A022001	A022101	A022102
Pacific Cancer Research Consortium NCORP	1	2	3	2	1	-	-	-	-
Regents of the University of Michigan	4	3	2	-	-	4	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	2	4	4	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-	1
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	2	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	2	-	4	-	-	-	-	7
UPMC Hillman Cancer Center LAPS	-	-	-	-	3	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	1	-	3	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-	-	-	1
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	1	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	3	-	9	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	-	8
University of Kentucky/Markey Cancer Center	-	-	4	-	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	-	1	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	2	-	-	-	-	-
University of Rochester LAPS	1	-	-	-	1	11	-	-	5
University of Texas Health Science Center at San Antonio	-	-	-	-	-	3	-	-	-
University of Texas MD Anderson Cancer Center LAPS	13	-	-	10	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	5	-	2	-	1	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	4	-	1	1	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	1	-	-	-	-	-	-	5
Wisconsin NCI Community Oncology Research Program	-	-	1	1	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	1	2	-	1	2	1	-	-
ALLIANCE	12	8	9	8	14	-	-	-	-
ECOG-ACRIN	2	16	8	14	1	-	-	-	-
NRG	3	9	8	10	2	-	-	-	-
Total	42	70	72	88	41	33	2	1	30

	A022104	CCTGCO32	CCTGNE1	EA2174	EA2176	EA2182	EA2192	EA2197	EA2222
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	13	-	-	-	-	-	-	-	-
Boston Medical Center	6	-	-	2	-	2	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	2	-	4	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	2	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	8	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-	1	2	-	-	-
Henry Ford Hospital	5	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	8	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	1	-	-	-	1	-
Northwestern University LAPS	-	-	-	-	1	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	2	-	-	-	-	-	-
Oregon Health and Science University	-	1	-	-	4	1	4	6	1

	A022104	CCTGCO32	CCTGNE1	EA2174	EA2176	EA2182	EA2192	EA2197	EA2222
Pacific Cancer Research Consortium NCORP	-	1	-	-	-	-	-	-	-
Regents of the University of Michigan	1	-	-	-	-	-	-	-	1
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	2	-	-
The Don and Sybil Harrington Cancer Center	1	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	17	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	4	-	-	-	-	-	-	1	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	5	3	-	-	4	1	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	1	-	-	1	3	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	2	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	1	1	-	-	-
University of Colorado Cancer Center LAPS	-	-	2	-	-	2	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-	2
University of Nebraska Medical Center	-	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	22	-	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	8	-	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	10	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	9	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	7	-	-	-	-	-	-	1	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-
Total	107	7	4	6	34	14	6	9	4

	NRGGI004	NRGG1005	NRGG1006	NRGG1008
Banner University Medical Center - Tucson	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	3	-	2
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	1
Boston Medical Center	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-
Dayton NCI Community Oncology Research Program	-	1	-	1
Fred Hutchinson Cancer Research Center LAPS	-	-	-	2
Gulf South Minority Underserved NCORP	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	5	-	1
Henry Ford Hospital	-	1	-	-
Houston Methodist Hospital	1	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	11	-	-
Loma Linda University Medical Center	-	-	-	1
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	1	-	-
Moffitt Cancer Center	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-
Northwell Health NCORP	-	1	-	1
Northwestern University LAPS	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-
Oregon Health and Science University	-	1	-	-

Pacific Cancer Research Consortium NCORP Regents of the University of Michigan	- - -	- - 1	-	-
	- - -		-	
	-	1		-
STCC at DHR Health Institute for Research and Development	-		-	1
Southeast Clinical Oncology Research Consortium NCORP		-	-	-
Sutter Cancer Research Consortium	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-
The West Clinic - Wolf River	-	-	-	4
UC Davis Comprehensive Cancer Center LAPS	-	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	1	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	6
University of Kansas Cancer Center - MCA Rural MU NCORP	-	2	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-
University of Nebraska Medical Center	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	1	1
University of Rochester LAPS	1	-	-	10
University of Texas Health Science Center at San Antonio	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	13	1	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	1	-	3
Virginia Mason Medical Center	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	4	-	-
ALLIANCE	-	-	-	-
ECOG-ACRIN	-	-	-	-
NRG	-	-	-	-
Total	15	35	1	34

